Correction: Efficacy of Bifidobacterium animalis subsp. lactis (BB-12), B. infantis and Lactobacillus acidophilus (La-5) probiotics to prevent gut dysbiosis in preterm infants of 28+0–32+6 weeks of gestation: a randomised, placebo-controlled, double-blind, multicentre trial: the PRIMAL Clinical Study Protocol


This article was previously published with errors. The published article has been revised with below corrections:

1. ‘Bifidobacterium longum’ has been updated as ‘Bifidobacterium animalis subsp. lactis’ in the article title, ‘Method and analysis’ of the ABSTRACT, ‘Strengths and limitations of this study’ section and in the last paragraph of the INTRODUCTION section.

2. The beginning statements in ‘Intervention and comparator’ of the METHOD AND ANALYSIS has been updated as ‘The probiotic formulation (verum), consisting of B. species and L. acidophilus corresponds to the formulation that has been most commonly used among the participating study sites in the past. The active intervention is provided once daily in single dose capsules. Each dose contains 1.5×10⁹ colony forming units (CFUs) of each of the strains: Lactobacillus acidophilus, Bifidobacterium animalis subsp. lactis and B. infantis.’

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.